Total and differential white blood cell counts, inflammatory markers, adipokines, and the metabolic syndrome in phase 1 of the clinical antipsychotic trials of intervention effectiveness study

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Objective: The metabolic syndrome is highly prevalent in patients with schizophrenia, and is associated with a state of chronic, low-grade inflammation. We investigated relationships between total and differential white blood cell (WBC) counts, inflammatory markers, adipokines and the metabolic syndrome in patients with schizophrenia. Method: For subjects with available data from the baseline/screening visit of the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial, WBC counts, inflammatory markers, and adipokines were investigated as predictors of the metabolic syndrome (and its components), using linear and binary logistic regression models, controlling for potential confounding effects of age, sex, race, smoking, fasting status, alcohol, and illicit drug use. Results: After controlling for potential confounders, blood CRP, interleukin-6, and leptin were significant predictors of all five individual components of the metabolic syndrome (as both continuous and categorical outcome measures). Furthermore, total WBC (OR=2.31, 95% CI 1.58-3.41, p. <. 0.01) and lymphocyte (OR=2.51, 95% CI 1.75-3.60, p<0.01) counts were the strongest predictors of current metabolic syndrome. Conclusions: Our findings provide the strongest evidence to date that measurement of total and differential WBC counts are germane to the clinical care of patients with schizophrenia, and that inflammation and adipokines are associated with metabolic disturbance in these patients.

Original languageEnglish (US)
Pages (from-to)30-35
Number of pages6
JournalSchizophrenia Research
Volume169
Issue number1-3
DOIs
StatePublished - Dec 1 2015

Fingerprint

Clinical Trials, Phase I
Adipokines
Leukocyte Count
Antipsychotic Agents
Schizophrenia
Logistic Models
Inflammation
Street Drugs
Leptin
Interleukin-6
Fasting
Patient Care
Leukocytes
Smoking
Alcohols
Outcome Assessment (Health Care)
Clinical Trials
Lymphocytes

Keywords

  • Adiponectin
  • C-reactive protein
  • Inflammation
  • Interleukin-6
  • Leptin
  • Metabolic syndrome
  • Schizophrenia
  • WBC

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Biological Psychiatry

Cite this

@article{5f2c1856c4b84ce1826306c11e305803,
title = "Total and differential white blood cell counts, inflammatory markers, adipokines, and the metabolic syndrome in phase 1 of the clinical antipsychotic trials of intervention effectiveness study",
abstract = "Objective: The metabolic syndrome is highly prevalent in patients with schizophrenia, and is associated with a state of chronic, low-grade inflammation. We investigated relationships between total and differential white blood cell (WBC) counts, inflammatory markers, adipokines and the metabolic syndrome in patients with schizophrenia. Method: For subjects with available data from the baseline/screening visit of the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial, WBC counts, inflammatory markers, and adipokines were investigated as predictors of the metabolic syndrome (and its components), using linear and binary logistic regression models, controlling for potential confounding effects of age, sex, race, smoking, fasting status, alcohol, and illicit drug use. Results: After controlling for potential confounders, blood CRP, interleukin-6, and leptin were significant predictors of all five individual components of the metabolic syndrome (as both continuous and categorical outcome measures). Furthermore, total WBC (OR=2.31, 95{\%} CI 1.58-3.41, p. <. 0.01) and lymphocyte (OR=2.51, 95{\%} CI 1.75-3.60, p<0.01) counts were the strongest predictors of current metabolic syndrome. Conclusions: Our findings provide the strongest evidence to date that measurement of total and differential WBC counts are germane to the clinical care of patients with schizophrenia, and that inflammation and adipokines are associated with metabolic disturbance in these patients.",
keywords = "Adiponectin, C-reactive protein, Inflammation, Interleukin-6, Leptin, Metabolic syndrome, Schizophrenia, WBC",
author = "Neil Mori and McEvoy, {Joseph Patrick} and Miller, {Brian J}",
year = "2015",
month = "12",
day = "1",
doi = "10.1016/j.schres.2015.10.001",
language = "English (US)",
volume = "169",
pages = "30--35",
journal = "Schizophrenia Research",
issn = "0920-9964",
publisher = "Elsevier",
number = "1-3",

}

TY - JOUR

T1 - Total and differential white blood cell counts, inflammatory markers, adipokines, and the metabolic syndrome in phase 1 of the clinical antipsychotic trials of intervention effectiveness study

AU - Mori, Neil

AU - McEvoy, Joseph Patrick

AU - Miller, Brian J

PY - 2015/12/1

Y1 - 2015/12/1

N2 - Objective: The metabolic syndrome is highly prevalent in patients with schizophrenia, and is associated with a state of chronic, low-grade inflammation. We investigated relationships between total and differential white blood cell (WBC) counts, inflammatory markers, adipokines and the metabolic syndrome in patients with schizophrenia. Method: For subjects with available data from the baseline/screening visit of the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial, WBC counts, inflammatory markers, and adipokines were investigated as predictors of the metabolic syndrome (and its components), using linear and binary logistic regression models, controlling for potential confounding effects of age, sex, race, smoking, fasting status, alcohol, and illicit drug use. Results: After controlling for potential confounders, blood CRP, interleukin-6, and leptin were significant predictors of all five individual components of the metabolic syndrome (as both continuous and categorical outcome measures). Furthermore, total WBC (OR=2.31, 95% CI 1.58-3.41, p. <. 0.01) and lymphocyte (OR=2.51, 95% CI 1.75-3.60, p<0.01) counts were the strongest predictors of current metabolic syndrome. Conclusions: Our findings provide the strongest evidence to date that measurement of total and differential WBC counts are germane to the clinical care of patients with schizophrenia, and that inflammation and adipokines are associated with metabolic disturbance in these patients.

AB - Objective: The metabolic syndrome is highly prevalent in patients with schizophrenia, and is associated with a state of chronic, low-grade inflammation. We investigated relationships between total and differential white blood cell (WBC) counts, inflammatory markers, adipokines and the metabolic syndrome in patients with schizophrenia. Method: For subjects with available data from the baseline/screening visit of the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial, WBC counts, inflammatory markers, and adipokines were investigated as predictors of the metabolic syndrome (and its components), using linear and binary logistic regression models, controlling for potential confounding effects of age, sex, race, smoking, fasting status, alcohol, and illicit drug use. Results: After controlling for potential confounders, blood CRP, interleukin-6, and leptin were significant predictors of all five individual components of the metabolic syndrome (as both continuous and categorical outcome measures). Furthermore, total WBC (OR=2.31, 95% CI 1.58-3.41, p. <. 0.01) and lymphocyte (OR=2.51, 95% CI 1.75-3.60, p<0.01) counts were the strongest predictors of current metabolic syndrome. Conclusions: Our findings provide the strongest evidence to date that measurement of total and differential WBC counts are germane to the clinical care of patients with schizophrenia, and that inflammation and adipokines are associated with metabolic disturbance in these patients.

KW - Adiponectin

KW - C-reactive protein

KW - Inflammation

KW - Interleukin-6

KW - Leptin

KW - Metabolic syndrome

KW - Schizophrenia

KW - WBC

UR - http://www.scopus.com/inward/record.url?scp=84953835152&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84953835152&partnerID=8YFLogxK

U2 - 10.1016/j.schres.2015.10.001

DO - 10.1016/j.schres.2015.10.001

M3 - Article

VL - 169

SP - 30

EP - 35

JO - Schizophrenia Research

JF - Schizophrenia Research

SN - 0920-9964

IS - 1-3

ER -